Dose–escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
   PubMed Web of Science ®Google Scholar
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet (London, England). 2012;380(9853):1606–1619.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterol United States. 2000;119(4):1148–1157.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut. 1997;40(4):443–448.
   PubMed Web of Science ®Google Scholar
• Jovani M, Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets. 2013;14(12):1433–1443.
   PubMed Web of Science ®Google Scholar
• Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases – update 2020. Pharmacol Res. 2020;158:104835.
   PubMed Web of Science ®Google Scholar
• Ylisaukko-Oja T, Torvinen S, Ventola H, et al. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab(). Scand J Gastroenterol. 2019;54(6):726–732.
   PubMed Web of Science ®Google Scholar
• Ma C, Huang V, Fedorak DK, et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014;40(9):1044–1055.
   PubMed Web of Science ®Google Scholar
• Duveau N, Nachury M, Gerard R, et al. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Dig Liver Dis. 2017;49(2):163–169.
   PubMedGoogle Scholar
• Sandborn WJ, Colombel J-F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis England. 2011;17(1):141–151.
   PubMed Web of Science ®Google Scholar
• Olivares D, Alba C, Pérez I, et al. Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis. Rev Esp Enfermedades Dig Organo of la Soc Esp Patol Dig Spain. 2019;111(11):846–851.
   PubMed Web of Science ®Google Scholar
• Iborra M, García-Morales N, Rubio S, et al. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Sci Rep. 2020;10(1):17774.
   PubMed Web of Science ®Google Scholar
• Bressler B, Williamson M, Sattin B, et al. Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure. J Can Assoc Gastroenterol. 2018;1(3):129–134.
   PubMedGoogle Scholar
• Haider SA, Yadav A, Perry C, et al. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol. 2020;13:1756284820959245.
   Web of Science ®Google Scholar
• Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn's disease patients treated with ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127–2143.
   PubMed Web of Science ®Google Scholar
• Hoque S, Puenpatom A, Boccaletti S, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020;7(1):e000476.
   PubMed Web of Science ®Google Scholar
• Gonczi L, Kurti Z, Rutka M, et al. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. BMC Gastroenterol. 2017;17(1):97.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Joensuu JT, Pirilä L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46(5):359–363.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterol United States. 2014;146(1):96–109.e1.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Lehtola E, Haapamäki J, Färkkilä MA. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scand J Gastroenterol. 2016;51(12):1476–1481.
   PubMed Web of Science ®Google Scholar
• Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis. 2013;7(9):730–735.
   PubMed Web of Science ®Google Scholar
• Molander P, Kemppainen H, Ilus T, et al. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol. 2020;55(1):34–40.
   PubMed Web of Science ®Google Scholar
• Eberl A, Hallinen T, Af Björkesten C-G, et al. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54(6):718–725.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group], et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a National Cohort Study. J Crohns Colitis. 2019;13(11):1401–1409.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Visuri I, Vigren L, et al.; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol. 2021;56(11):1304–1311.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–1432.
   PubMed Web of Science ®Google Scholar
• Loftus EVJ, Seigel CA, Panaccione R, et al. Corticosteroid dose reduction with vedolizumab treatment of Crohn’s disease. Eur Gastroenterol J. 2015;2(suppl 1):A254.
   Google Scholar
• Ylisaukko-Oja T, Torvinen S, Aaltonen J, et al. Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice. Biologicals. 2019;58:50–56.
   PubMed Web of Science ®Google Scholar